UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.

Design Therapeutics, a US-based gene therapy spinout of University of Wisconsin-Madison,  has filed for a $100m initial public offering that will allow SR One, the venture capital firm funded by pharmaceutical firm GlaxoSmithKline, to exit. Founded in 2017, Design Therapeutics is developing small molecule drugs known as gene targeted chimeras to treat inherited nucleotide repeat…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.